A practical reference on bremelanotide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-18 and is reviewed periodically as new material appears.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
1 November – A pooled analysis indicates that globally over half of all preschool-aged children and over two-thirds of all nonpregnant women of reproductive age are deficient in at least one of three micronutrients each. The study notes required data is scarce and such deficiencies can constrain physical and (neurocognitive) development and compromise health. 2 November – Scientists show that cells move faster in thicker (higher viscosity) fluids. Cancer cells can form memory of extracellular fluid, helping them to form distant cancerous colonies more efficiently when exposed to fluids of higher viscosities. 3 November – Astronomers using the IXPE space observatory report that 4U 0142+61, a magnetar found 13,000 light-years from Earth, likely has a solid surface with no atmosphere. 4 November – The discovery of Gaia BH1, a binary system containing what is likely the closest known black hole to Earth, is reported by astronomers in the U.S. 6–18 November – The 2022 United Nations Climate Change Conference (COP27) on climate change mitigation takes place in Sharm el-Sheikh, Egypt. 7 November The first clinical trial of laboratory-grown red blood cells transfused into people begins. Scientists warn about summarized effects of climate change on insects, among other novel stressors, which may "drastically reduce our ability to build a sustainable future based on healthy, functional ecosystems", providing several recommended mitigation options. The development of organic artificial neurons that function in and with biological systems, partly (see e.g.
The APPI interface for LC–MS was developed simultaneously by Bruins and Syage in 2000. APPI is another LC–MS ion source/ interface for the analysis of neutral compounds that cannot be ionized using ESI. This interface is similar to the APCI ion source, but instead of a corona discharge, the ionization occurs by using photons coming from a discharge lamp. In the direct-APPI mode, singly charged analyte molecular ions are formed by absorption of a photon and ejection of an electron. In the dopant-APPI mode, an easily ionizable compound (dopant) is added to the mobile phase or the nebulizing gas to promote a reaction of charge-exchange between the dopant molecular ion and the analyte. The ionized sample is later transferred to the mass analyzer at high vacuum as it passes through small orifice skimmers.
De Vries acted as a close confidant to Nabil B., the crown witness in the Marengo trial whose own brother, alongside his lawyer, were assassinated by Taghi's organisation for exposing their inner workings. The person who is suspected of killing De Vries, is a relative of the person who is in charge of Taghi's hit squad, which gives the Dutch authorities more reason to believe that Taghi's organisation is responsible for the killing. However, it is still unclear who gave the order of the shooting, since Taghi himself was already in a high-security prison at the time of the shooting.
Sources: en.wikipedia.org
==== Freeze-drying ==== This method is the most expensive out of all dehydration methods but provides the advantage of long stable shelf life at room temperature and an excellent retention of soluble nutrients (nitrogen protein and other solids). The product undergoes quick freeze at 10 °C (50 °F) and is then dried at a moderate temperature inside a strong vacuum. Due to the expensive nature of the equipment, the final product price is higher than tempeh preserved through other methods.
I am born of a people who are heroes and heroines [...] Patient because history is on their side, these masses do not despair because today the weather is bad. Nor do they turn triumphalist when, tomorrow, the sun shines. [...] Whatever the circumstances they have lived through and because of that experience, they are determined to define for themselves who they are and who they should be. In April 1997, Mbeki articulated the elements that comprise the African Renaissance: social cohesion, democracy, economic rebuilding and growth, and the establishment of Africa as a significant player in geopolitical affairs. Two months later, Vusi Maviembela, an advisor to Mbeki, wrote that the African Renaissance was the "third moment" in post-colonial Africa, following decolonization and the spread of democracy across the continent in the early 1990s. Deputy President Mbeki codified his beliefs, and the reforms that would comprise them, in the "African Renaissance Statement" given August 13, 1998. In March 1998, United States President Bill Clinton visited Botswana, Ghana, Rwanda, Senegal, South Africa, and Uganda in a 12-day tour, which he proclaimed as the "beginning of a new African renaissance" following apartheid, colonialism, and the Cold War. While Clinton praised the continent's increase in democratically elected governments, news outlets countered that many African leaders operated in one-party states. The outbreak of the Eritrean–Ethiopian War in May 1998 and Second Congo War in August 1998 led to further doubts of a peaceful future.
protein sorting Also protein targeting. The set of biological mechanisms by which proteins are directed and transported to appropriate destinations within or outside of the cell. Proteins must often be routed into the interior of organelles, embedded within a membrane, or secreted into the extracellular environment in order to serve their functions, and information contained in the protein itself instructs this delivery process. In eukaryotic cells, an expansive network of organelles and pathways is specialized to facilitate protein sorting, including the endoplasmic reticulum and the Golgi apparatus.
Particles such as whole cells or cell debris, which would clog a packed bed column, readily pass through a fluidized bed. EBA can therefore be used on crude culture broths or slurries of broken cells, thereby bypassing initial clearing steps such as centrifugation and filtration, which is mandatory when packed beds are used. In older EBA column designs, the feed flow rate is kept low enough that the solid packing remains stratified and does not fluidize completely. Hence EBA can be modelled as frontal adsorption in a packed bed, rather than as a well-mixed, continuous-flow adsorber.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.